These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 21632464

  • 21. Novel Ras antagonist blocks human melanoma growth.
    Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, Pehamberger H, Gana-Weisz M, Ben-David E, Kloog Y, Wolff K.
    Proc Natl Acad Sci U S A; 1999 Nov 23; 96(24):14019-24. PubMed ID: 10570191
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
    Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC.
    J Bone Miner Res; 2013 Dec 23; 28(12):2476-89. PubMed ID: 23703870
    [Abstract] [Full Text] [Related]

  • 24. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
    Stärkel P, Charette N, Borbath I, Schneider-Merck T, De Saeger C, Abarca J, Leclercq I, Horsmans Y.
    Mol Carcinog; 2012 Oct 23; 51(10):816-25. PubMed ID: 21882255
    [Abstract] [Full Text] [Related]

  • 25. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
    Reif S, Weis B, Aeed H, Gana-Weis M, Zaidel L, Avni Y, Romanelli RG, Pinzani M, Kloog Y, Bruck R.
    J Hepatol; 1999 Dec 23; 31(6):1053-61. PubMed ID: 10604579
    [Abstract] [Full Text] [Related]

  • 26. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
    Karussis D, Abramsky O, Grigoriadis N, Chapman J, Mizrachi-Koll R, Niv H, Kloog Y.
    J Neuroimmunol; 2001 Nov 01; 120(1-2):1-9. PubMed ID: 11694313
    [Abstract] [Full Text] [Related]

  • 27. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B, Ehrlich M, Haklai R, Kloog Y.
    Methods Enzymol; 2008 Nov 01; 439():467-89. PubMed ID: 18374183
    [Abstract] [Full Text] [Related]

  • 28. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y.
    Cancer Chemother Pharmacol; 2008 Jan 01; 61(1):89-96. PubMed ID: 17909812
    [Abstract] [Full Text] [Related]

  • 29. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, Kim YB, Yim H, Jeong SY.
    Int J Oncol; 2013 Feb 01; 42(2):657-66. PubMed ID: 23292448
    [Abstract] [Full Text] [Related]

  • 30. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
    Goldberg L, Haklai R, Bauer V, Heiss A, Kloog Y.
    J Med Chem; 2009 Jan 08; 52(1):197-205. PubMed ID: 19072665
    [Abstract] [Full Text] [Related]

  • 31. BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK.
    Beck SE, Jung BH, Del Rosario E, Gomez J, Carethers JM.
    Cell Signal; 2007 Jul 08; 19(7):1465-72. PubMed ID: 17317101
    [Abstract] [Full Text] [Related]

  • 32. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
    George J, Afek A, Keren P, Herz I, Goldberg I, Haklai R, Kloog Y, Keren G.
    Circulation; 2002 May 21; 105(20):2416-22. PubMed ID: 12021230
    [Abstract] [Full Text] [Related]

  • 33. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
    Jiang C, Song T, Li J, Ao F, Gong X, Lu Y, Zhang C, Chen L, Liu Y, He H, Huang O.
    Mol Neurobiol; 2017 Jan 21; 54(1):779-787. PubMed ID: 27021020
    [Abstract] [Full Text] [Related]

  • 34. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
    Clarke HC, Kocher HM, Khwaja A, Kloog Y, Cook HT, Hendry BM.
    J Am Soc Nephrol; 2003 Apr 21; 14(4):848-54. PubMed ID: 12660318
    [Abstract] [Full Text] [Related]

  • 35. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.
    Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y.
    Mol Cancer Ther; 2006 Sep 21; 5(9):2337-47. PubMed ID: 16985068
    [Abstract] [Full Text] [Related]

  • 36. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.
    Nickl-Jockschat T, Arslan F, Doerfelt A, Bogdahn U, Bosserhoff A, Hau P.
    Int J Oncol; 2007 Feb 21; 30(2):499-507. PubMed ID: 17203233
    [Abstract] [Full Text] [Related]

  • 37. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
    Chai G, Liu N, Ma J, Li H, Oblinger JL, Prahalad AK, Gong M, Chang LS, Wallace M, Muir D, Guha A, Phipps RJ, Hock JM, Yu X.
    Cancer Sci; 2010 Sep 21; 101(9):1997-2004. PubMed ID: 20550523
    [Abstract] [Full Text] [Related]

  • 38. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid.
    Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y.
    J Biol Chem; 1995 Sep 22; 270(38):22263-70. PubMed ID: 7673206
    [Abstract] [Full Text] [Related]

  • 39. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
    Makovski V, Haklai R, Kloog Y.
    Int J Cancer; 2012 Mar 15; 130(6):1420-9. PubMed ID: 21500191
    [Abstract] [Full Text] [Related]

  • 40. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
    Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y.
    Mol Cancer Ther; 2007 Jun 15; 6(6):1765-73. PubMed ID: 17541036
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.